GlassScriptPhysician profile
Elizabeth Thacker Goff
NPI 1841648748
$8,057.25
in general payments reported to CMS, 2019-2025
49 companies · $1,154 in 2025
The $1,154 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $458 · 2021: $1,042 · 2022: $1,999 · 2023: $1,419 · 2024: $1,780 · 2025: $1,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,338 · Entertainment: $14.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,338.11 |
| Entertainment | $14.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,506.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $774.63 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $589.22 | 2019-2025 | |
| Abbvie INC. | $578.63 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $416.14 | 2020-2025 | Jardiance |
| Amgen INC. | $402.26 | 2021-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $374.25 | 2020-2024 | Farxiga, Airsupra, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $318.18 | 2021-2025 | Trintellix |
| Abbott Laboratories | $317.65 | 2020-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $316.09 | 2020-2025 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $212.55 | 2019-2025 | Gardasil 9, Rotateq, Capvaxive |
| Esperion Therapeutics, INC. | $176.27 | 2021-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $163.17 | 2020-2023 | |
| Janssen Pharmaceuticals, INC | $146.42 | 2022-2024 | Xarelto |
| Teva Pharmaceuticals USA, INC. | $141.72 | 2020-2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Goff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.